Pair Name | Mangiferin, Cisplatin | ||
Phytochemical Name | Mangiferin (PubChem CID: 5281647 ) | ||
Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Drug Name | Cisplatin |
Adverse Reactions | Myelosuppression, dry mouth and throat, fever, dry stools. This was inferred hot nature anticancer drug. |
Recommendations | Cold: Anemarrhena asphodeloides; Urena lobataL; Artemisia scoparia; Swertia mussotii; Swertia pseudochinensis; Gentiana manshurica; Gossampinus malabarica; Pyrrosia sheareri; Pyrrosia sheareri; Iris domestica; Gentiana scabra; Pyrrosia sheareri; Pyrrosia petiolosa |
Reference | ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899. ref_link |
Pair Name | Mangiferin, Cisplatin | |||
Disease Info | Nephrotoxicity | Investigative | ||
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Down-regulation | Expression | CAPN1 | hsa823 | |
Down-regulation | Cleavage | CASP12 | hsa100506742 | |
Down-regulation | Cleavage | CASP3 | hsa836 | |
Up-regulation | Expression | HMOX1 | hsa3162 | |
Down-regulation | Expression | MYC | hsa4609 | |
Up-regulation | Expression | NFE2L2 | hsa4780 | |
Up-regulation | Expression | PIK3CA | hsa5290 | |
Up-regulation | Expression | SOD2 | hsa6648 | |
In Vitro Model | MCF-7 | Invasive breast carcinoma of no special type | Homo sapiens (Human) | CVCL_0031 |
SK-RC-45 | Clear cell renal cell carcinoma | Homo sapiens (Human) | CVCL_4016 | |
EAC-E2G8 | Malignant neoplasms of the mouse mammary gland | Mus musculus (Mouse) | CVCL_WJ08 | |
In Vivo Model | Four weeks old male swiss albino mice were used for this study. | |||
Result | The study reveals a mechanistic basis of mangiferin action against cisplatin induced nephrotoxicity. Since Mangiferin shows synergistic anticancer activity with cisplatin, it can be considered as a promising drug candidate, to be used in combination with cisplatin. |
No. | Title | Href |
---|---|---|
1 | Mangiferin Ameliorates Cisplatin Induced Acute Kidney Injury by Upregulating Nrf-2 via the Activation of PI3K and Exhibits Synergistic Anticancer Activity With Cisplatin. Front Pharmacol. 2018 Jun 18;9:638. doi: 10.3389/fphar.2018.00638. | Click |